Evergreen Capital Management LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the first quarter, HoldingsChannel.com reports. The firm owned 1,470 shares of the medical research company’s stock after buying an additional 65 shares during the quarter. Evergreen Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $402,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TMO. Capital Financial Planning LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $27,000. Hanson McClain Inc. raised its holdings in shares of Thermo Fisher Scientific by 263.9% during the fourth quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. Truvestments Capital LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $29,000. Capital Investment Advisory Services LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $35,000. Finally, Liberty Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $35,000. 87.96% of the stock is owned by institutional investors.
A number of equities analysts have commented on TMO shares. Barclays increased their target price on Thermo Fisher Scientific from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Deutsche Bank upped their price target on Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. UBS Group upped their price target on Thermo Fisher Scientific to $305.00 and gave the company a “buy” rating in a research report on Monday, March 25th. BTIG Research upped their price target on Thermo Fisher Scientific to $310.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Finally, Robert W. Baird upped their price target on Thermo Fisher Scientific from $270.00 to $288.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $295.92.
In related news, CEO Marc N. Casper sold 50,713 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $273.21, for a total value of $13,855,298.73. Following the completion of the transaction, the chief executive officer now directly owns 302,193 shares in the company, valued at $82,562,149.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the completion of the transaction, the chief financial officer now owns 40,029 shares of the company’s stock, valued at $10,739,380.41. The disclosure for this sale can be found here. Insiders sold 53,488 shares of company stock valued at $14,600,474 over the last quarter. 0.45% of the stock is currently owned by company insiders.
TMO stock opened at $286.24 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.69 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $114.01 billion, a PE ratio of 25.74, a P/E/G ratio of 1.87 and a beta of 1.08. Thermo Fisher Scientific Inc. has a 1 year low of $202.83 and a 1 year high of $288.07.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.74 by $0.07. The business had revenue of $6.13 billion during the quarter, compared to analyst estimates of $6.04 billion. Thermo Fisher Scientific had a return on equity of 17.06% and a net margin of 12.89%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.50 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 12.2 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 16th. Investors of record on Friday, June 14th will be given a $0.19 dividend. The ex-dividend date is Thursday, June 13th. This represents a $0.76 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 6.83%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: Balanced Fund
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.